Streetbeat News

Analyst Ratings

IART

Truist Securities analyst Richard Newitter maintains a 'Hold' rating on Integra Lifesciences (NASDAQ:IART) and lowers the price target from $41 to $39.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 6:15 pm

HLT

Truist Securities analyst Patrick Scholes maintains a 'Hold' rating on Hilton Worldwide Holdings (NYSE:HLT) and raises the price target from $172 to $175.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 6:12 pm

TMO

Thermo Fisher Scientific Inc. (NYSE:TMO) reported mixed Q3 results and lowered its FY23 guidance. The company posted adjusted earnings of $5.69 per share, slightly above expectations, but sales were slightly below estimates. The company also revised its 2023 revenue and EPS forecasts downwards. Following the announcement, several analysts including Morgan Stanley, Raymond James, Citigroup, and RBC Capital lowered their price targets on Thermo Fisher. Keybanc analyst downgraded the stock from Overweight to Sector Weight.

Portfolio Pulse from Lisa Levin

October 26, 2023 | 6:11 pm

HSII

Truist Securities analyst Tobey Sommer has maintained a 'Hold' rating on Heidrick & Struggles Intl (NASDAQ:HSII) and lowered the price target from $32 to $27.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 6:10 pm

TMO

Thermo Fisher Scientific Inc (TMO) has been downgraded to Sector Weight from Overweight by KeyBanc Capital Markets analyst Paul Knight, following a Q3 revenue miss and lowered outlook for FY23. The company's management expressed concerns about cash conservatism from biotech customers, weakness in China, possible destocking, and overall industry decline. Other analysts from Morgan Stanley, Raymond James, and Citigroup also lowered their price targets for TMO.

Portfolio Pulse from Lekha Gupta

October 26, 2023 | 6:09 pm

FBIN

Truist Securities analyst Keith Hughes has maintained a 'Buy' rating on Fortune Brands (NYSE:FBIN) but lowered the price target from $75 to $65.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 6:08 pm

EW

Truist Securities analyst Richard Newitter has maintained a 'Buy' rating on Edwards Lifesciences (NYSE:EW) but lowered the price target from $83 to $76.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 6:04 pm

AVY

Truist Securities analyst Michael Roxland has maintained a 'Buy' rating on Avery Dennison (NYSE:AVY), but lowered the price target from $215 to $209.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 6:03 pm

APH

Truist Securities analyst William Stein maintains a 'Buy' rating on Amphenol (NYSE:APH) but has lowered the price target from $101 to $97.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 6:01 pm

LYV

Guggenheim analyst Curry Baker maintains a Buy rating on Live Nation Entertainment (NYSE:LYV) and raises the price target from $124 to $125.

Portfolio Pulse from Benzinga Newsdesk

October 26, 2023 | 5:57 pm